So we finally get a product? I'm getting excited for this. Any news about this?
Bimatoprost finishing up Phase IIb trial!
Collapse
X
-
Comment
-
Thanks. Dang, I wish the results were already available so we could see the efficiency and more importantly dosage/vehicle.Comment
-
Few pages before there was a quote from Allergan CEO who claims that if this is good it will be on market around 2020.Comment
-
You're going to have to do your own homework on that one. If you doubt what I'm saying then you should look into it some more.Comment
-
I am not speculating, I posted the link to the interview with allergan CEO David Pyott in which he gave this time frame earlier in this thread. If you have a problem with how long he expected it to take, take it up with him. Or the CEO of actavis, the company that took allergan over. Or just make up your own facts, as many on here do. But don't try to call me out when all I'm doing is relaying evidence for the benefit of those who care about such things.Comment
-
I am not speculating, I posted the link to the interview with allergan CEO David Pyott in which he gave this time frame earlier in this thread. If you have a problem with how long he expected it to take, take it up with him. Or the CEO of actavis, the company that took allergan over. Or just make up your own facts, as many on here do. But don't try to call me out when all I'm doing is relaying evidence for the benefit of those who care about such things.Comment
-
In a market moving interview with the CEO of Allergan, Cramer was first to learn that the FDA had voted in favor of the company's new volumizing filler called Voluma.
You didn't offend me, my response was directed to the poster that I quoted.
This is the video, watch it around 3:22 for his estimate as to the time frame. I posted this before and the simple fact that it exists was somehow considered irrelevant by some on here because the time frame given wasn't what they wanted to hear. Some of the people on here just believe whatever they want and others do their best to form opinions based on the available evidence, so this post is really for the latter. The others can continue as they normally do.Comment
-
http://www.cnbc.com/id/100702571
You didn't offend me, my response was directed to the poster that I quoted.
This is the video, watch it around 3:22 for his estimate as to the time frame. I posted this before and the simple fact that it exists was somehow considered irrelevant by some on here because the time frame given wasn't what they wanted to hear. Some of the people on here just believe whatever they want and others do their best to form opinions based on the available evidence, so this post is really for the latter. The others can continue as they normally do.Comment
-
Comment
-
Looks like another drug potentially approaches approval, Bim just finished it's data collection and will be(im assuming) releasing it's final results in January according to this trial information:
Now i've heard mixed things with this drug, i've seen people use the weaker solution with fairly decent results, however Allergan may not release it if it's not much better than minoxidil, but personally I would love another option!
So anyone have more info on this stuff or hear anything related to the trial?
35YrsAfter also posts as CITNews and works at Dr. Cole's office - forhair.com - Cole Hair Transplant, 1045 Powers Place, Alpharetta, Georgia 30009 - Phone 678-566-1011 - email 35YrsAfter at chuck@forhair.com
The contents of my posts are my opinions and not medical advice
Please feel free to call or email me with any questions. Ask for ChuckComment
-
Because if the results of the phase IIb dose escalating study are far superior to minoxidil, this product would be pushed to market ASAP. Your quote is old and based on older information. Just wait until January, many things will come to light. I'm done going back and forth with you about nothing.Comment
-
-
Prostaglandin F2a (PGF2a) induces cyclin D1 expression and DNA synthesis in Swiss 3T3 cells. In order to assess which signaling mechanisms are implicated in these processes, we have used both a pharmacological approach and interfering mutants. We demonstrate that PGF2a induces extracellular-signal-regulated kinase (ERK1-2) and p38MAPK activation, and inhibition of any of these signaling pathways completely blocks PGF2a-stimulated DNA synthesis. We also show that ERK1-2, but not p38MAPK activation is required to induce cyclin D1 expression, strongly suggesting that the concerted action of cyclin D1 gene expression and other events are required to induce complete phosphorylation of retinoblastoma protein and S-phase entry in response to PGF2a.Comment
-
I Find a document. It deals with a complaint for Patent Infringement : Duke University and Allergan Vs Atopex. Here : http://patentdocs.typepad.com/files/duke-v-apotex.pdf
"The Patent in suit :
On December 9, 2014, the ’962 patent, entitled “Compositions and Methods for Treating Hair Loss Using Non-Naturally Occurring Prostaglandins,” issued to Duke University.
A copy of the ’962 patent is attached to this Complaint as Exhibit A. "Comment
Comment